Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types
Hermann Einsele, Hossein Borghaei, Robert Z. Orlowski, et al.
Cancer (2020) Vol. 126, Iss. 14, pp. 3192-3201
Open Access | Times Cited: 169

Showing 1-25 of 169 citing articles:

Bispecific Antibodies: From Research to Clinical Application
Jiabing Ma, Yicheng Mo, Menglin Tang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 228
The landscape of bispecific T cell engager in cancer treatment
Yingtang Zhou, Ming‐Guo Liu, Fei Ren, et al.
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 156
Engineering protein-based therapeutics through structural and chemical design
Sasha B. Ebrahimi, Devleena Samanta
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 155
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
José Saura‐Esteller, Milon de Jong, Lisa A. King, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 130
Advances in antibody-based therapy in oncology
Sacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, et al.
Nature Cancer (2023) Vol. 4, Iss. 2, pp. 165-180
Closed Access | Times Cited: 119
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 119
Advances in diagnosis and management of cancer of the esophagus
Nathaniel Deboever, Christopher M. Jones, Kohei Yamashita, et al.
BMJ (2024), pp. e074962-e074962
Open Access | Times Cited: 41
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 34
New agents and regimens for diffuse large B cell lymphoma
Liang Wang, Linrong Li, Ken H. Young
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 122
Advances in PSMA-targeted therapy for prostate cancer
Fujin Wang, Li Z, Xiaoqian Feng, et al.
Prostate Cancer and Prostatic Diseases (2021) Vol. 25, Iss. 1, pp. 11-26
Closed Access | Times Cited: 92
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
Alessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 84
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
Julien Edeline, Roch Houot, Aurélien Marabelle, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 74
Oncolytic Adenovirus: Prospects for Cancer Immunotherapy
Yaqi Zhao, Zheming Liu, Lan Li, et al.
Frontiers in Microbiology (2021) Vol. 12
Open Access | Times Cited: 67
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
Marlena Surowka, Wolfgang Schaefer, Christian Klein
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 57
Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches
Heinz Läubli, Sam C. Nalle, Daniel Maslyar
Cancer Immunology Research (2022) Vol. 10, Iss. 12, pp. 1423-1432
Open Access | Times Cited: 53
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Deep Shah, Brian W. Soper, Lindsay S. Shopland
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 40
Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle
Angelika M. Starzer, Matthias Preusser, Anna S. Berghoff
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 39
Antibody variable region engineering for improving cancer immunotherapy
Hantao Lou, Xuetao Cao
Cancer Communications (2022) Vol. 42, Iss. 9, pp. 804-827
Open Access | Times Cited: 38
Strategies for clinical dose optimization of T cell-engaging therapies in oncology
Kathryn Ball, Simon J. Dovedi, Pavan Vajjah, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 38
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
Diana Simão, Kevin Zarrabi, José Leão Mendes, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1412-1412
Open Access | Times Cited: 27
Progression in immunotherapy for advanced prostate cancer
Hao Liang, Yang Liu, Jiao Guo, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 27
BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
Shi‐Wei Huang, Chih‐Ming Pan, Yu‐Chuan Lin, et al.
Advanced Science (2023) Vol. 10, Iss. 17
Open Access | Times Cited: 23
Targeted immunotherapy: harnessing the immune system to battle multiple myeloma
Limei Xu, Caining Wen, Jiang Xia, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs
Qi Zhao, Hong Zong, Pingping Zhu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination
Zhaokai Zhou, Yumiao Mai, Ge Zhang, et al.
Cancer Letters (2024) Vol. 598, pp. 217079-217079
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top